Quote this publication Share Print

CASODEX

-
Opinions on drugs - Posted on May 31 2006

Reason for request

Inclusion on the list of medicines reimbursed by National Health Insurance and approved for use by hospitals and various public services

-


Actual benefit

Important

The Actual Benefit of Casodex is substantial.


Improvement in actual benefit

V (absence)

Casodex (50 mg, 150 mg) does not provide any improvement in Actual Benefit (level V) in the current management of patients with nonmetastatic prostate cancer at a locally advanced stage, as adjuvant therapy to radical prostatectomy or radiotherapy.


Contact Us

Évaluation des médicaments